Michael R. Briggs
Tufts Cummings School of Veterinary Medicine, USA
Biography
He have a long career as a leader in the pharmaceutical industry at Director level or above and he is the founder of Woodland Pharmaceuticals.He is passionate about advancing treatment of the deadliest cancers. Our team’s approach involves building relevant in vitro and in vivo models and my focus over the past 10 years has been to increase the likelihood of effective translation to the clinic by establishing primary patient tumor models that are much closer to the patient tumor biology than the traditional cancer cell lines. The highest unmet medical need in oncology therapy is cancer recurrence. Our ultimate goal is to move to experimental systems using patient-derived tumor models that better inform us of the diversity we are likely to see in the clinic, thus improving clinical outcomes to positively impact patient health and make the drug discovery process more productive and efficient. The idea is to test the prospective drug in low passage patient tumor samples before we get to the clinical trial, and thus may be likened to a “preclinical trial”.